Norverapamil

Norverapamil ((±) -Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

Product Specifications

CAS Number

[67018-85-3]

Product Name Alternative

(±) -Norverapamil; D591

UNSPSC

12352005

Hazard Statement

H301

Target

Calcium Channel; Drug Metabolite; P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/norverapamil.html

Solubility

10 mM in DMSO

Smiles

N#CC(C(C)C)(CCCNCCC1=CC=C(OC)C(OC)=C1)C2=CC=C(OC)C(OC)=C2

Molecular Formula

C26H36N2O4

Molecular Weight

440.58

Precautions

P264-P270-P330-P405-P501

References & Citations

[1]Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014 Aug 1;210 (3) :456-66.|[2]Pauli-Magnus C, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293 (2) :376-82.|[3]Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50 (3-4) :290-302.|[4]Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34 (3-4) :163-8.